anti cd8b (Bio X Cell)
Bio X Cell is a verified supplier 
Bio X Cell manufactures this product 
97
Structured Review
Bio X Cell
anti cd8b
Anti Cd8b, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1147 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd8b/Anti-CD8+Cd8A+Antibody/us12558351-425-36-37
Average 97 stars, based on 1147 article reviews
Anti Cd8b, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1147 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd8b/Anti-CD8+Cd8A+Antibody/us12558351-425-36-37
Average 97 stars, based on 1147 article reviews
anti cd8b - by Bioz Stars,
2026-11
97/100 stars
Images
Related Articles
Injection:Article Title: Methods of treatment with CD8 T cell-mediated immune therapy Article Snippet: Radiation was delivered with a small animal radiation research platform (Xstrahl, Atlanta, GA) with cone beam-CT image guidance as previously described (Gunderson et al., PLoS One 14:e0211117, 2019). .. Anti-CD4 (GK1.5), anti-CD8α (2.43) and Article Title: Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse Article Snippet: .. For antibody-depletion of CD8 + and CD4 + T cells, mice were intraperitoneally injected with 125 μg Article Title: Compositions and methods for enhancing cancer immune checkpoint therapy Article Snippet: For antibody treatments, mice were given 100 μg antibody via intraperitoneal (i.p.) injection at day 6, 9, 12 post tumor cells injection using following antibodies: anti-PD1 (clone 29F.1A12) or isotype (clone 2A3) from BioXCell. .. Lymphocyte Depletion To evaluate the role of specific subsets of immune effector cells in mice, CD4+T cells, CD8+T cells, and NK cells were depleted with 100 μg of i.p. injected anti-CD4 (BioXcell, GK1.5), 100 ug of Article Title: Parity and lactation induce T-cell-mediated breast cancer protection Article Snippet: .. Seven days before AT3-OVA tumour challenge, non-randomized mice were injected intraperitoneally with 200 μg IgG2 isotype control combined with 200 μg anti-CD4 (GK1.5, Bio X Cell Leganon), anti-CD8α (YTS, Bio X Cell), Article Title: CREB5 promotes immunotherapy resistance via tumor-intrinsic collagen matrix deposition Article Snippet: .. For competition studies with CD8-depletion arm, mice were treated with 200 μg of Article Title: Perturbation of calreticulin potentiates CD8+ T cell-mediated antitumor immunity. Article Snippet: For the immunotherapy group, mice were treated as indicated with 200 μg of rat monoclonal anti-PD-1 (clone 29F.1A12; Bio X Cell) on days 6, 9, and 12 via intraperitoneal (i.p.) injection. .. For the depletion group, mice were treated with 200 μg of Article Title: Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse. Article Snippet: .. For antibody-depletion of CD8+ andCD4+ T cells, mice were intraperitoneally injected with 125μg Control:Article Title: Parity and lactation induce T-cell-mediated breast cancer protection Article Snippet: .. Seven days before AT3-OVA tumour challenge, non-randomized mice were injected intraperitoneally with 200 μg IgG2 isotype control combined with 200 μg anti-CD4 (GK1.5, Bio X Cell Leganon), anti-CD8α (YTS, Bio X Cell), other:Article Title: A novel small molecule Enpp1 inhibitor improves tumor control following radiation therapy by targeting stromal Enpp1 expression. Article Snippet: When tumors were approximately 5 mm in average diameter at approximately 10–14 days following implantation, mice were randomized to receive treatment with CT-guided radiation using the Small Animal Radiation Research Platform (SARRP) from XStrahl. Tumor Implantation:Article Title: Perturbation of calreticulin potentiates CD8+ T cell-mediated antitumor immunity. Article Snippet: For the immunotherapy group, mice were treated as indicated with 200 μg of rat monoclonal anti-PD-1 (clone 29F.1A12; Bio X Cell) on days 6, 9, and 12 via intraperitoneal (i.p.) injection. .. For the depletion group, mice were treated with 200 μg of |
![( A ) Schematic for treating single-cell suspensions from MC38 tumors +/− 1 μM RSL3 ex vivo (left). Frequencies of viable CD8 + (left), CD4 + Tconv (middle), and T reg cells (right) from tumor single-cell suspensions as a percentage of CD45 + cells +/− 1 μM RSL3 for 4 hours. Data from n = 6 mice. ( B ) Experimental schematic for measuring tumor growth in wild-type versus Aifm2 -deficient T reg cell mice. ( C ) Growth of MC38 tumors in Treg. Aifm2 +/+ ( n = 5) versus Treg. Aifm2 Δ / Δ ( n = 6) mice. ( D ) Frequency of Foxp3 + T reg cells as a percentage of total CD45 + immune cells (left) and CD8:T reg cell ratio (right) in MC38 tumors at day 29. ( E ) Experimental schematic for measuring tumor growth in wild-type versus Aifm2 -deficient T reg cell mice treated +/− <t>200</t> <t>μg</t> <t>anti-CD8b.2</t> intraperitoneally every 7 days beginning with tumor inoculation. ( F ) Growth of MC38 tumors in Treg. Aifm2 +/+ + isotype ( n = 5), Treg. Aifm2 +/+ + anti-CD8b.2 ( n = 5), Treg. Aifm2 Δ / Δ + isotype ( n = 5), and Treg. Aifm2 Δ / Δ + anti-CD8b.2 ( n = 5). ( G ) Experimental schematic for measuring tumor growth in wild-type versus Aifm2 -deficient T reg cell mice treated +/− 10 mg/kg liproxstatin (injected intraperitoneally daily). ( H ) Growth of MC38 tumors in Treg. Aifm2 +/+ + vehicle ( n = 3), Treg. Aifm2 +/+ + Lip-1 ( n = 4), Treg. Aifm2 Δ / Δ + vehicle ( n = 5), and Treg. Aifm2 Δ / Δ + Lip-1 ( n = 5). For all plots, * P < 0.05, ** P < 0.01, and *** P < 0.001 by Student’s t test [(A) and (D)] or two-way ANOVA [(C), (F), and (H)], mean ± SEM.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_9571/pmc12829571/pmc12829571__sciadv.aea3703-f4.jpg)